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Abstract
Lovastatin is an anti-cholesterol agent that was produced by Aspergillus terreus using solid state fermentation (SSF).
During this fermentation process, sulochrin is also produced as an unwanted co-metabolite. However, our previous
result showed that sulochrin had potential as antidiabetes because it is an inhibitor agent of α-glucosidase. In this paper,
we reported our observation on lovastatin and sulochrin production pattern in relation with inhibitor α-glucosidase
activity during eleven days fermentation of A. terreus koji (SSF) ethyl acetate extract. Koji obtained from solid state
fermentation with rice as the substrate and incubated at room temperature, sample is taken daily for eleven day (D-1 to
D-11). Lovastatin and sulochrin production was measured by Liquid Chromatography- Mass Spectrometer based on
their molecular weight m/z 404.5 and 332.3 respectively. The inibitory activity is measured by inhibition model of koji
extract against α-glucosidase (EC 3.2.1.20) from Saccharomyces cereviceae. The results show that lovastatin
production was started on the day 2 (0.04 mg/g) and achieving the optimal production on day 7 (11.46 mg/g), while
sulochrin production was started on day 4 (0.60 mg/g) and keep produced until the end of fermentation period at Day 11
(3.11 mg/g). Koji extract was started to show inhibitory to α-glucosidase activity on Day 5 (IC50= 23.34 µg/mL) and
keep showed activity until Day 11 (IC50=3.33 µg/mL). These results suggest that inhibitory activity of koji extract to αglucosidase activity have relation with sulochrin biosynthesis production.
Keywords: α-glucosidase inhibitor, Aspergillus terreus, lovastatin, SSF, sulochrin

scale lovastatin production have been developed using
A. terreus [3,5,6]. In submerged fermentation, its yield
is proportional to the amount of biomass, with the high
cell density causing the increase of the fermentation
broth viscosity and the difficulty in stirring and oxygen
mass transfer; an alternative strategy to produce
lovastatin is by solid state fermentation (SSF) [7].

1. Introduction
Lovastatin (Mevinolin, Monocolin K, and MevacorTM)
is potent drug for lowering blood cholesterol. Lovastatin
act as competitively inhibition to the enzyme 3-hidroxy3-methylglutaryl coenzyme A reductase (HMG-CoA)
with catalyzes the rate limiting step of cholesterol
biosynthesis [1]. In the recent years, lovastatin has also
been reported as a potential therapeutic agent for the
treatment of various types of tumors because it
suppresses tumor growth in vivo by inhibiting the
synthesis of non-sterol isoprenoid compounds [2].
Lovastatin is produced as a secondary metabolite by the
fungi Penicillium sp, Monascus ruber, and Aspergillus
terreus [3].

In recent years, reseacher have show an increasing
interest in solid state fermentation (SSF) as potential
alternative of submerged fermentation, because it uses
economical substrate, requires fewer processing and
down-streaming stages, utilizes lesser power and
generates lesser effluent [8]. Moreover, SSF has higher
product yield and offers better product stability [2].
Except the low substrate cost and low energy
consumption, the SSF process can offer a good
environment for fungi to grow, therefore high mycelia
density and high lovastatin production can be expected
[2,7,9].

A. terreus is widely used lovastatin producer of the
industrial importance [4], which is extensively excreted
from fungal cells into the medium in the form of β–
hydroxy acid-mevinolinicacid [5]. As a kind of
secondary metabolite of fungi, lovastatin is an
intracellular product and mostly accumulated in
mycelia. Submerged fermentation processes for large-

Nevertheless, such a microorganism of the rich
secondary metabolism as A. terreus is also capable of
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In previous result, sulochrin isolated from the ethyl
acetate extract of A. terreus by SSF using rice as
substrate (koji), showed potential as α-glucosidase
inhibitor and demonstrated depressed postprandial
blood glucose level in mice [12]. Hence, A. terreus not
only could produce anti cholesterol agent but also have
possibility to produce anti diabetes. Therefore, the aim
of this work was to do observation on lovastatin and
sulochrin production pattern in relation with inhibitory
activity to α-glucosidase during seven days fermentation
of A. terreus koji (SSF) ethyl acetate extract.

2. Methods
Microorganism and growth condition. A wild-type
strain A. terreus is a collection of Research Center for
Chemisrty-Indonesian Institute of Sciences, was used in
the present study. It was grown on maintained media
slant containing: yeast extract (0.4%), malt (1%),
dextrose (0.4%) and agar (2%), spores were collected
after 7 days at 28 oC.
Solid state fermentation. Solid substrate (1 kg rice)
washed twice with water, drained, and autoclaved at
121 oC for 15 min with addition of water (1:1). After
cooling, media was inoculated with 50 ml (5%) of A.
terreus culture grow on sporulation medium [13]. Media
was thoroughly mixed, placed in sterile alummunium
tray (10x10 cm) and incubated for 11 day at 28 °C.
Every day, one tray was harvested to analyse lovastatin
and sulochrin content, inhibition assay for α-glucosidase
activity, reduced sugar were assayed by Somogyi
Nelson (DNS) method, and organic nitrogen was
determinant by Kjedahl method.
Inhibition assay for α-glucosidase activity. The
reaction mixture consisting 250 μL of 20 mM pnitorpehenyl α-D-glucopyranoside (Sigma Chemical
Co), 495 μL of 100 mM phosphate buffer (pH 7.0)
adding to flask contain 5 μL of sample dissolved in
DMSO at various concentrations (3.125 to 25 μg/mL).
The reaction mixture was pre-incubated for 5 min at 30
°C, the reaction was start by adding 250 μL αGlucosidase (0.075 unit) (EC 3.2.1.20 from Wako Pure
Chemical Industry) incubation was continued for 15
min. The reaction stopped by adding 2 mL 0f 0.1 M
Na2CO3. Enzymatic activity was quantified by

measuring absorbance at 400 nm. IC50 value was
defined as the concentration of α-glucosidase inhibitor
that inhibited 50% of α-glucosidase activity.
Extraction method. Fermented sample was extracted
by 300 mL of ethyl acetate in 250 mL Erlenmeyer flask,
shaked at 150 rpm for 1 day. The etyl acetate extract
was concentrated in vacuo to give brown pasta.
Analytical methods. The concentration of lovastatin
and sulochrin was determined with Liquid
Chromatography-Mass
Spectrometer
(Mariner
Biospectrometry), system ESI (Electrospray Ionisation),
positive ion mode, using Supelco C18 column (150 mm
x 2 mm 1.d), acetonitril:water (95:5) was used as mobile
phase, flow rate 1 mL/min.

3. Results and Discussion
The main composition of rice is used as substrate in SSF
of A. terreus is starch. Its must be hydrolyzed into
glucose to acetate, which is one of the compounds
involved in biosynthesis of lovastatin. Although, A.
terreus can produce amylase to hydrolize starch, in the
beginning of the SSF process, there is not enough
amylase secreted by cells. The amount of reduced sugar
increased in the first three days due to the hydrolysis of
starch by amylase which is secreted through the rapid
growth of fungi [7]. After five days the reduced sugar
was kept almost constant because of the dynamic
balance between glucose formation and consumption
(Fig. 1). Similiar patern also occur for protein content in
the substrate after fermentation processed N content was
increased as metabolism processed during fermentation
of A. terreus.
Our experimental results showed that sulochrin in ethyl
acetate extract appeared at 1.7 min in a liquid
chromatography, earlier than lovastatin which appeared
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This compound is also a product of the polyketide
synthase (PKS) pathway [11] and, as mevinolinic acid,
is formed from malonyl-CoA and acetyl-CoA [4]. For
the purpose of lovastatin production, sulochrin is
considered as an unwanted co-metabolite due to the
toxicities associated with the contaminants and/or due to
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Figure 1. Time Courses of Reduced Sugar (♦) and Protein
Content (•) during SSF Process
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glucosidase inhibitors have been isolated from the
fermentation broth and solid of certain microorganisms,

at 2.4 min (Fig. 2) with their molecular weight m/z
333.13 [M+H]+, with m/z 405.17 [M+H]+ respectively
(Fig. 3). In Fig. 4, the evolution curved for lovastatin
and sulochrin production in SSF were presented. The
formation of lovastatin was start earlier on Day 2 (0.04
mg/g), which explained that although lovastatin is a
kind of secondary metabolite, its accumulation in
mycelia seems growth related, which is different with
the phenomena in submerged fermentation [7]. The
maximum lovastatin yield was achieved on day 7 (11.46
mg/g), after that, the lovastatin yield was decreasing
slightly. While sulochrin production was started on day
4 (0.60 mg/g) and keep produced until the end of
fermentation period at Day 11 (3.11 mg/g).
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In our previous study on sulochrin isolation, we found
that sulochrin showed α-glucosidase inhibitory activity
not only at in vitro assay but also at in vivo experiment
as measured in plasma glucose levels after sucrose
administered to mice [12,13]. This result is similar with
other published results which showed that several α-
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4. Conclusion
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Figure 4. Time Course of Lovastatin (♦) and Sulochrin (•)
Production during A. terreus SSF Process

such as validamycin A from growth of Streptomyces
hygroscopicus, Acarbose isolated from fermentation
broth of Actinoplanes spp., reported traditionally
fermented soybean product (Touchi) was found to
possess strong α-glucosidase inhibitory activity [14,15].
Although, screening α-glucosidase inhibitory compound
from solid state fermentation with rice as substrate have
not reported yet.
The results of α-glucosidase inhibitory activity assay
during the process of A. terreus with rice (koji)
presented in Tabel 1. Koji extract was started to show
inhibitory to α-glucosidase activity on day 5 (IC50=
23.34 µg/mL), which sulochrin produced was 1.46
mg/g. Activity of α-glucosidase inhibitory increasing
rapidly during the first 7 days of fermentation process,
this phenomenon might be due to the increase of
secondary metabolite production during fermentation.
However, during the end of fermentation process, the
activities are varied, this might be due to the present of
metabolite(s) other than sulochrin that also responsible
for inhibitory activity of α-glucosidase.
Although, it is suggest that the metabolites might still
have correlation with sulochriin biosynthetic pathway.
During lovastatin fermentation process, this compound
is present at polyketide pathway that originate from
malonyl-CoA and acetyl-Co-A, which as same as
sulochrin biosynthesis pathway [4]. Sulochrin may be
further modified to form geodin (C17H12Cl2O7; m/z
399.183) [11] this suggestion is supported with the LCMS result (m/z [M+CH3CN+H]+ = [M+42] = 441.95).
Geodin is known to have ability to enhance (stimulate)
glucose uptake by rat adipocytes and sulochrin is the
precursor of geodin [16]. However, the present of other
inhibitor compound(s) that has no relation with
sulochrin production is still possible, since as mention
earlier other α-glucosidase inhibitors by other microbes
have been reported [14,15].

The maximum yield of lovastatin was achieved on day 7
(11.40 mg/g), while the maximum sulochrin was
achieved on day 8 (5.26 mg/g) at SSF using rice as a
substrate of A. terreus α-glucosidase inhibitor activity is
assumed to relate to the biosynthesis sulochrin.
Therefore, SSF of A. terreus is a potential system to be
used for production of anti-cholesterol and/or
antidiabetes compounds.

References
[1] A.W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff,
C. Hoffman, Proc. Natl. Acad. Sci. 77 (1980)
3957.
[2] H.R. Valera, J. Gomes, S. Lakshmi, R. Gururaja, S.
Suryanarayan, D. Kumar, Enzyme. Microb.
Technol. 37/5 (2005) 521.
[3] H. Hajjaj, N. Peter, D. Philippe, App. Environ.
Microbiol. 67 (200) 2596.
[4] M. Bizukojc, S. Ledakowicz, J. Biotechol. 132/4
(2007) 453.
[5] J.L. Casas Lopez, J.A. Sanches Perez, J.M.
Fernandez Sevilla, F.G. Acien Fernandez, E.
Molina Grima, Y. Christy, Enzyme. Microb.
Technol. 33/8 (2003) 270.
[6] M.S. Kumar, S.K. Jana, V. Senthil, S. Shashanka,
S.V. Kumar, A.K. Sadhukhan, Process Biochem.
36 (2000) 363.
[7] P.L. Wei, Z.N. Xu, P.L. Cen, J. Zhejiang Univ. Sci
A. 8/9 (2007) 1521.
[8] D. Kumar, V.K. Jain, G. Shanker, A. Srivastava,
Process Biochem. 38 (2003) 1725.
[9] B.J. Xu, Q.J. Wang, X.Q. Jia, C.K. Sung,
Biotechnol. Bioprocess Eng. 10/1 (2005) 78.
[10] V.A. Vinci, T.D. Hoerner, A.D. Coffman, T.G.
Schimmel, R.L. Dabora, A.C. Kirpeker, C.L. Ruby,
R.W. Stieber, J. Ind. Microbiol. 8 (1991) 113.
[11] R.D. Couch, G.M. Gaucher, J. Biotech. 108 (2004)
171.
[12] R.T. Dewi, A. Darmawan, S.D.S. Banjarnahor, H.
Mulyani, M. Angelina, Minarti, Proceeding of the
International Conference on Pharmacy and
Advanced Pharmaceutical Sciences, Yogyakarta,
Indonesia, 2009. p. 44.
[13] R.T. Dewi, Y. Iskandar, M. Hanafi, L.B.S.
Kardono, M. Angelina, D.I. Dewijanti, S.D.S.
Banjarnahor, Pak. J. Biol. Sci. 10/18 (2007) 3131.
[14] Y.P. Zhu, L.J. Yin, Y.Q. Cheng, K. Yamaki, Y.
Mori, Y.C. Su, L.T. Li, Food Chem. 109 (2008)
737.
[15] F. Hiroyuki, Y. Tomohide, Elsevier 70 (2001) 219.
[16] S. Sato, N. Okusa, A. Ogawa, T. Ikenoue, T. Seki,
T. Tsuji, J. Antibiot. 58 (2005) 583.

